Hidradenitis suppurativa and association with stroke: systematic review and meta-analysis

References

• Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol. 2018;59(4):267–277.
   PubMed Web of Science ®Google Scholar
• Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9–16.
   PubMedGoogle Scholar
• Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7(2):e31810.
   PubMed Web of Science ®Google Scholar
• Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760–764.
   PubMed Web of Science ®Google Scholar
• Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171–e177.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and All-Cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152(4):429–434.
   PubMed Web of Science ®Google Scholar
• Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82(2):366–376.
   PubMed Web of Science ®Google Scholar
• Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations. J Am Acad Dermatol. 2021. DOI:10.1016/j.jaad.2021.01.059
   Web of Science ®Google Scholar
• Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36(2):47–54.
   PubMed Web of Science ®Google Scholar
• Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27–S35.
   PubMed Web of Science ®Google Scholar
• Caprio FZ, Sorond FA. Cerebrovascular disease: primary and secondary stroke prevention. Med Clin North Am. 2019;103(2):295–308.
   PubMed Web of Science ®Google Scholar
• Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol. 2019;155(7):797–802.
   PubMed Web of Science ®Google Scholar
• Hung CT, Chiang CP, Chung CH, et al. Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: a nationwide, population-based, cohort study in Taiwan. J Dermatol. 2019;46(10):867–873.
   PubMed Web of Science ®Google Scholar
• Parker JG, Ali Y, Randall D, et al. Risk of hemorrhagic and ischemic stroke subsequent to diagnosis for hidradenitis suppurativa: real-world data from a large urban midwestern US patient population. J Am Acad Dermatol. 2020;83(6):AB187.
   Web of Science ®Google Scholar
• Ward RKR, Liu B, Green C, et al. Hidradenitis suppurativa is associated with increased odds of stroke, coronary artery disease, heart failure, and PAD: a population-based analysis in the United States. J Am Acad Dermatol. 2019;8(4):AB1.
   Google Scholar
• Miller IMA, Zarchi K, Rytgaard H, et al. Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol. 2018;179:790–791.
   PubMedGoogle Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–1298.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Hanni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798.
   PubMed Web of Science ®Google Scholar
• Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673–685.
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Werring DJ. Stroke: causes and clinical features. Medicine (Abingdon). 2020;48(9):561–566.
   PubMedGoogle Scholar
• Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and Meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142–1155.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North american clinical management guidelines for hidradenitis suppurativa: a publication from the United States and canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90.
   PubMed Web of Science ®Google Scholar
• Flood KS, Porter ML, Kimball AB. A visit guide for hidradenitis suppurativa-managing a complex disease in a busy clinic. J Am Acad Dermatol. 2021;84(3):e155–e160.
   PubMed Web of Science ®Google Scholar
• Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):330–334.
   PubMedGoogle Scholar
• Katramados AV. The stroke book. 2nd ed. Torbey MTSM, editor. New York: Cambridge University Press; 2013.
   Google Scholar
• Joseph Bailey AM, Oi-Yee Li H, Tan MG, et al. Hidradenitis suppurativa and major adverse cardiac events: a systematic review and Meta-analysis. J Am Acad Dermatol. 2021;84(3):844–848.
   PubMed Web of Science ®Google Scholar
• Pinter A, Kokolakis G, Rech J, et al. Hidradenitis suppurativa and concurrent psoriasis: comparison of epidemiology, comorbidity profiles, and risk factors. Dermatol Ther (Heidelb). 2020;10(4):721–734.
   PubMed Web of Science ®Google Scholar